Medicines labeled for the same conditions
Alternatives to olaparib
19 other medicines are given the same way (oral) and in the same FDA class as olaparib or labeled mainly for the same use (breast cancer); 3 are in its class, poly(adp-ribose) polymerase inhibitors: talazoparib, rucaparib camsylate and abiraterone and niraparib; the others include 6 kinase inhibitors, 3 aromatase inhibitors and 2 estrogen agonist/antagonists (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as olaparib?
Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Olaparibpoly(adp-ribose) polymerase inhibitor | this medicine | none listed | n/a | No | No current entry |
| Talazoparibpoly(adp-ribose) polymerase inhibitor · same class | Breast cancer, Prostate cancer | none listed | n/a | No | No current entry |
| Rucaparib camsylatepoly(adp-ribose) polymerase inhibitor · same class | Prostate cancer | none listed | n/a | No | No current entry |
| Abiraterone and niraparibcytochrome p450 17a1 inhibitor · same class | Prostate cancer | none listed | n/a | No | No current entry |
| Everolimusmtor inhibitor immunosuppressant | Breast cancer | 14 labelers | $26.32 per tablet 10 mg tablet | No | A presentation being discontinued |
| Anastrozolearomatase inhibitor | Breast cancer | 24 labelers | $0.142 per tablet 1 mg tablet | No | No current entry |
| Letrozolearomatase inhibitor | Breast cancer | 19 labelers | $0.145 per tablet 2.5 mg tablet | No | No current entry |
| Tamoxifenestrogen agonist/antagonist | Breast cancer | 10 labelers | $0.277 per tablet 20 mg tablet | Yes | No current entry |
| Exemestanearomatase inhibitor | Breast cancer | 10 labelers | $0.748 per tablet 25 mg tablet | No | No current entry |
| Palbociclibkinase inhibitor | Breast cancer | none listed | n/a | No | A presentation being discontinued |
| Abemaciclibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Lapatinib ditosylatekinase inhibitor | Breast cancer | 3 labelers | n/a | Yes | No current entry |
| Methyltestosteroneandrogen | Breast cancer | 2 labelers | n/a | No | No current entry |
| Ribociclibkinase inhibitor | Breast cancer | none listed | $289.72 per unit 600 mg daily dose | No | No current entry |
| Toremifeneestrogen agonist/antagonist | Breast cancer | 2 labelers | $19.60 per tablet 60 mg tablet | Yes | No current entry |
| Capivasertib | Breast cancer, Prostate cancer | none listed | n/a | No | No current entry |
| Elacestrantestrogen receptor antagonist | Breast cancer | none listed | n/a | No | No current entry |
| Tucatinibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
| Imlunestrantestrogen receptor antagonist | Breast cancer | none listed | n/a | No | No current entry |
| Neratinibkinase inhibitor | Breast cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Olaparib: the full record
- label, generics, price, shortages, recalls